What should an ideal vaccine postlicensure safety system be?

American Journal of Public Health

Volumn 99, Issue SUPPL. 2, 2009, Pages

  Griffin, Marie R ^a,b   Braun, M Miles ^c   Bart, Kenneth J ^c  

^a VANDERBILT UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; SMALLPOX VACCINE;

CLINICAL ASSESSMENT; DISEASE SURVEILLANCE; DRUG FATALITY; DRUG SAFETY; GUILLAIN BARRE SYNDROME; HUMAN; INFLUENZA; INFORMATION SYSTEM; INTUSSUSCEPTION; MEDICAL INFORMATICS; MEDICAL INFORMATION; MENINGOCOCCOSIS; MORBIDITY; MYOCARDITIS; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; POLIOMYELITIS; POSTMARKETING SURVEILLANCE; PUBLIC HEALTH SERVICE; REVIEW; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINE PRODUCTION;

EID: 70350056595     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2008.143081     Document Type: Review

References (25)

1. Nathanson N, Langmuir AD. The Cutter incident: poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. Am J Hyg. 1964;78:16-81.
2. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep. 1999;48:1007.
3. Centers for Disease Control and Prevention. Update: Guillain Barré syndrome among recipients of Menactra meningococcal conjugate vaccine - United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep. 2006;55:1120-1124.
4. Institute of Medicine. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: National Academy Press; 2007.
5. Ellenberg SS, Foulkes MA, Midthun K, Goldenthal KL. Evaluating the safety of new vaccines: summary of a workshop. Am J Public Health. 2005;95:800-807. (Pubitemid 40593740)
6. McClellan M. Drug safety reform at the FDA - pendulum swing or systematic improvement? N Engl J Med. 2007;356:1700-1702.
7. Jacobson RM, Adegbenroo A, Penkratz VS, et al. Adverse events and vaccination - the lack of power and predictability of infrequent events in prelicensure study. Vaccine. 2001;19:2428-2433.
8. Fritzell B. Detection of adverse events: what are the current sensitivity limits during clinical development? Vaccine. 2002;20:547-548.
9. Andrews NJ. Statistical assessment of the association between vaccination and rare adverse events post licensure. Vaccine. 2001;20:S49-S53.
10. Food and Drug Administration. Guidance for industry on pharmacovigilance planning. Available at: http://www.fda.gov/cber/gdlns/ichpvp.htm. Accessed December 28, 2008.
11. Kohl KS, Bonhoeffer J, Chen R, et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf. 2003;12:335-340. (Pubitemid 36705478)
12. Chen RT, De Stefano F, Davis RL, et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ. 2000;78:186-194.
13. Verstraeten T, De Stefano F, Chen RT, et al. Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guide. Expert Rev Vaccines. 2003;2:21-29. (Pubitemid 36559936)
14. Andersen MM, Ronne T. Side effects with Japanese encephalitis vaccine. Lancet. 1991;337:1044.
15. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type I diabetes. N Engl J Med. 2004;350:1398-1404.
16. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA. 2003;290:1763-1766.
17. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995;345:567-569.
18. Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopenic purpura. Br J Clin Pharmacol. 2003;55:107-111. (Pubitemid 36110846)
19. Kaye JA, del Mar Miler-Montes M, Jack H. Mumps, measles and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ. 2001;322:460-463.
20. Horne PR, Saarlas KN, Hinman AR. Costs of immunization registries: experiences from the All Kids Count II projects. Am J Prev Med. 2000;19:94-98.
21. Centers for Disease Control and Prevention. Immunization registry progress - United States. MMWR Morb Mortal Wkly Rep. 2002;51:760-762.
22. Goodwin H, Nash M, Gold M, et al. Vaccination of children following a previous hypotonic-hyporesponsive episode. J Paediatr Child Health. 1999;35:549-552.
23. O'Hallahan J, Lennon D, Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J. 2004;23:S293-S298. (Pubitemid 44544512)
24. Ameratunga S, Macmillan A, Stewart J, et al. Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy. Vaccine. 2005;23:2231-2234. (Pubitemid 40341458)
25. Gellin BG, Mailbach EW, Marcuse EK. Do parents understand immunizations? A national telephone survey. Pediatrics. 2000;106:1097-1102.